Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
82 hedge funds and large institutions have $117M invested in Kindred Biosciences, Inc. in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 8 closing their positions.
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
47% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 19
6% more funds holding
Funds holding: 77 → 82 (+5)
4% more capital invested
Capital invested by funds: $113M → $117M (+$4.16M)
34% less call options, than puts
Call options by funds: $158K | Put options by funds: $239K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
+$990K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$880K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$690K |
| 4 |
BlackRock
New York
|
+$441K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$320K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAI
General American Investors
New York
|
-$881K |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$595K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$186K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$153K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$153K |
KIN Hedge Fund Activity: Q4 2020 in Review
82 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q4 2020, worth a combined $117M — up 3.7% from $113M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new KIN positions and 8 closed out — a net gain of 5 holders — while 28 added to existing stakes and 19 trimmed.
The largest buyer was Ariel Investments, adding an estimated $990K. The largest seller was General American Investors, cutting an estimated $881K.
- 82 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q4 2020, up from 77 in Q3 2020.
- Funds reported $117M of Kindred Biosciences, Inc. stock for Q4 2020, up 3.7% quarter-over-quarter.
- 13 funds opened new Kindred Biosciences, Inc. positions in Q4 2020 and 8 closed out, a net change of +5 holders.
- The largest Kindred Biosciences, Inc. buyer in Q4 2020 was Ariel Investments, an estimated $990K added.
- The largest Kindred Biosciences, Inc. seller in Q4 2020 was General American Investors, an estimated $881K sold.
Based on aggregated 13F filings for Q4 2020.